<DOC>
	<DOC>NCT01681472</DOC>
	<brief_summary>The purpose of this study is to compare the concentration of [6R] 5,10-methylene-THF, 5-formyl-THF, 5-methyl-THF and THF in the tumor, in adjacent mucosa and in plasma in patients with colon cancer receiving two different does of Modufolin® and Levoleucovorin (Isovorin®) respectively (60 and 200 mg/m2).</brief_summary>
	<brief_title>PK/PD Investigation of Modufolin® in Plasma, Tumor and Adjacent Mucosa in Patients With Colon Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Tetrahydrofolates</mesh_term>
	<criteria>Patients must have operable colon cancer that is amenable to curative surgery.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Colon cancer</keyword>
	<keyword>5,10-methylenetetrahydrofolate</keyword>
	<keyword>Rectal Neoplasms</keyword>
	<keyword>Colorectal Neoplasms</keyword>
	<keyword>Intestinal Neoplasms</keyword>
	<keyword>Gastrointestinal Neoplasms</keyword>
	<keyword>Digestive System Neoplasms</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>